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Proteins of the Bcl-2 family are important regulators of cell fate. The role of these proteins in controlling mitochondrial apoptotic
processes has been extensively investigated, although exact molecular mechanisms are incompletely understood. However, mounting
evidence indicates that these proteins also function at the endoplasmic reticulum and other locations within the cell. Both pro- and anti-
apoptotic Bcl-2 family members can regulate endoplasmic reticulum calcium, cellular pH and endoplasmic reticulum resident proteins. In this
review, we discuss the activities and potential targets of Bcl-2 family members at the endoplasmic reticulum and other cellular locations.
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The Bcl-2 family of proteins can be separated into two
functional categories, either pro- or anti-apoptotic (recently
reviewed in Ref. [1]). Although cellular functions for these
proteins are well recognized, the precise molecular mecha-
nism by which these proteins regulate cell death (either
positively or negatively) is controversial and the subject of
many ongoing investigations. To be designated as a Bcl-2
family member, a protein must possess at least one of the
four conserved Bcl-2 homology (BH) domains and have a
demonstrable effect on apoptosis. Interactions between
family members mediated by BH domains are critical for
many aspects of their function. However, the sequence
diversity of these proteins suggests a level of diversity in
function that has not been fully explored: indeed, the
number of both pro- and anti-apoptotic members exceeds
those needed even in current models of multi-step regulation
of apoptosis (e.g. Ref. [2]).
The three-dimensional structure of Bcl-XL [3], Bid [4],
Bax [5], Bcl-2 [6], and Bcl-w [7,8] are more similar than0167-4889/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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has two central hydrophobic helices surrounded by amphi-
pathic helices in a structure that resembles the pore-forming
domain of the bacterial diphtheria toxin. Consistent with the
known structures, there is good in vitro evidence that some
of these proteins can form pores or channels in lipid bilayers
(reviewed in Ref. [9]). Thus, a combination of protein:pro-
tein interactions and pore/channel formation are postulated
to constitute the main molecular mechanisms of Bcl-2
activity. Since many of the Bcl-2 family members have
similar structures, the sequence diversity may determine
subtle aspects of the regulation of these proteins through
specific protein:protein interactions.
Bcl-2, the prototype for the Bcl-2 family, contains all
four BH domains (BH1–4) and a carboxyl-terminal hydro-
phobic sequence called a tail-anchor. Unlike many other
tail-anchor proteins which are targeted to a single subcellu-
lar location, Bcl-2 is localized to the endoplasmic reticulum
(ER), nuclear envelope, and outer mitochondrial membrane
in mammalian cells [10]. This broad localization allows Bcl-
2 to function at spatially distinct regions of the cell, thereby
enhancing its anti-apoptotic activity. The discovery that Bcl-
2 targets via a tail-anchor sequence occurred at roughly the
same time as the elucidation of the mechanisms that regulate
targeting and integration of tail-anchor sequences in subcel-
lular membranes [11,12]. These studies suggested that it
Table 1
Extra-mitochondrial locations for selected Bcl-2 family members
Anti-apoptotic Bcl-2 proteins
Bcl-2 ER and nuclear envelope [10]










Bik ER [55], cytosol
Bmf Cytoskeleton [63]
Bid Cytosol and membranes (ER?) [76]
Spike ER [53]
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proteins by generating tail-anchor mutants. By using this
approach, we demonstrated that Bcl-2 does not need to be
located at both physiological sites (the ER and mitochon-
dria) to function; in fact in stably transfected cells, Bcl-2
prevents apoptosis from either organelle with overlapping
but non-identical specificity [13]. The use of organelle-
targeted mutants has been very important for studies ana-
lyzing the contribution of the ER to the regulation of
apoptosis. The general details of the construction of these
mutants and their use are described in this review in the
section titled Mutants of Bcl-2 with restricted subcellular
localization.
Since Liu et al. [14] discovered the importance of cyto-
chrome c in the induction of apoptosis, mitochondria have
become the central focus for many investigations into the
molecular mechanisms regulating apoptosis (reviewed in
Ref. [15]). Many of these studies have shown that mitochon-
dria are a point of convergence for extrinsic and intrinsic
apoptotic pathways. Mitochondria also undergo extensive
alterations during cell death, but the events leading up to
mitochondrial dysfunction are poorly understood. Recently,
a number of studies have highlighted the ER as a key
upstream signaling organelle for the regulation of apoptosis,
and consistent with this, several members of the Bcl-2 family
are also located at the ER (Table 1). ER-specific functions for
most of these proteins have yet to be discovered despite the
emerging evidence that the ER is an important location for
the regulation of apoptosis. One physiologically relevant
candidate is control of ER Ca2 + levels. However, Bcl-2
family members also interact with proteins on the ER that are
not involved in Ca2 + homeostasis.2. ER CA2+ and anti-apoptotic Bcl-2 proteins
The original observation that Bcl-2 regulates intracellular
Ca2 + levels is now a decade old [16]. However, the effect ofBcl-2 on intracellular and intra-organellar Ca2 + levels is still
controversial and the literature contains conflicting data.
Overexpression of Bcl-2 in human breast epithelial cells
results in increased [Ca2 +]ER [17], and in mouse lymphoma
cells it increases Ca2 + uptake into the ER [18]. Although the
mechanism by which Bcl-2 increases [Ca2 +]ER is not clear,
breast cells expressing Bcl-2 have increased sarco(endo)-
plasmic reticulum Ca2 +-ATPase (SERCA) pump expression
[17]. Consistent with these results, increased expression of
SERCA by transfection also increases [Ca2 +]ER [19]. In-
creased [Ca2 +]ER, or rather the maintenance of ER Ca
2 +
levels, promotes cell proliferation and growth, thus inhibit-
ing cell death [18]. However, other studies indicate that Bcl-
2 expression causes decreased [Ca2 +]ER in HeLa cells [20],
human prostate cancer cells [21], HEK-293 (human embry-
onic kidney) cells and R6 fibroblasts [22]. These decreases
in [Ca2 +]ER by Bcl-2 are postulated to protect cells from
apoptosis by limiting the amount of Ca2 + released into the
cytoplasm following an apoptotic stimulus. Reducing the
amount of Ca2 + released into the cytoplasm in turn limits
the uptake of Ca2 + into the mitochondria [23], which can
lead to mitochondrial permeability transition and mitochon-
drial dysfunction (reviewed in Ref. [24]). In this case, lower
[Ca2 +]ER is due to a Bcl-2 mediated increase in leakage of
Ca2 + from the ER by an unidentified mechanism [20],
which may involve the pore-forming capabilities of this
molecule.
The above discrepancies between the reported effects of
Bcl-2 on [Ca2 +]ER may be due to differences in cell lines,
Bcl-2 expression levels, or the methodologies used to
measure Ca2 +. Intra-organellar Ca2 + levels have been
measured by using either fluorescent dyes or Ca2 +-binding
proteins, both of which have important limitations.
Indirect measurements of [Ca2 +]ER using a cytoplasmic
dye (e.g. Fura-2 or Indo-1) can detect the amount of Ca2 +
released from the ER. The accumulation of Ca2 + in the
cytoplasm is usually stimulated by the inhibition of the
SERCA pump with either thapsigargin or tert-butyl-benzo-
hydroquinone. Measurements of this kind require an even
distribution of the fluorescent dye in the cytoplasm and are
dependent on the amount of SERCA inhibitor added. When
Bcl-2 was reported to increase [Ca2 +]ER, 1 AM thapsigargin
was used [17]; by contrast, studies reporting decreased
[Ca2 +]ER used f 100 nM thapsigargin [21,22]. As Bcl-2
interacts with SERCA directly [17], it is possible that this
interaction makes SERCA more resistant to thapsigargin. If
SERCA remains active following treatment with the lower
amount of thapsigargin, it would cause [Ca2 +]ER to appear
lower. In addition, dyes like Fura-2 may have unexpected
effects on cell physiology when combined with toxic drugs.
Direct measurements of organellar Ca2 + have been made
with targeted mutants of the photoprotein aequorin [25] or
the fluorescent cameleon protein [26]. However, use of
these organelle-targeted mutants requires genetic manipula-
tion of cells and measurements cannot be taken until
expression is sufficient (f 24–36 h post-infection/transfec-
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may alter the normal Ca2 + balance, thus complicating the
interpretation of results.
Another disadvantage of ER-targeted aequorin is that ER
Ca2 + depletion (usually accomplished by ionomycin) and
refilling of ER with extracellular sources of Ca2 + is re-
quired. These manipulations may significantly alter mito-
chondrial function, cellular Ca2 + regulation and other
aspects of cell physiology. Thus, the inherent limitations
of current methods used to measure Ca2 + may influence the
outcome of the studies on the role of Ca2 + in apoptotic
signaling pathways. In addition, many investigations com-
pare cells overexpressing Bcl-2 to control-transfected cell
lines. Overexpressed Bcl-2 is certainly biologically relevant
to several pathologies; however, transient overexpression of
Bcl-2 in experimental systems can be toxic to cells due to
membrane damage from rapid incorporation of large
amounts of tail-anchor peptide into the bilayer [27]. Thus
Bcl-2 expression levels (both the population average as well
as variation between individual cells) may have unexpected
effects on [Ca2 +]ER levels as well as membrane function.
Despite the limitations of current methods for measuring
Ca2 + at steady state, it is clear that changes in cytoplasmic
Ca2 + levels can trigger apoptosis. Indeed blocking Ca2 +
signaling with cytoplasmic chelators inhibits cell death [28].
Release of Ca2 + from the ER initiates cell death by
activating the Ca2 +-dependent protease calpain, caspases
[29], and/or by directly causing mitochondrial dysfunction
(reviewed in Ref. [24]). Crosstalk between the ER and
mitochondria is a critical mechanism for determining cell
fate [30]. Indeed, we have demonstrated that ceramide, a
lipid second messenger, triggers apoptosis through the early
loss of mitochondrial membrane potential [31], a process
that is usually mediated by increased cytoplasmic Ca2 +
[32]. Importantly, ceramide-induced cell death is inhibited
by ER-localized Bcl-2 [31].
Bcl-2 is not the only anti-apoptotic family member that
influences [Ca2 +]ER: Bcl-XL also decreases both the expres-
sion of the inositol-1,4,5-triphosphate receptor (IP3R) and
the amount of Ca2 + released following T cell stimulation
[33]. In addition, in artificial lipid bilayers, luminal Ca2 +
can inhibit cation-selective Bcl-XL channels [34]. The effect
of other anti-apoptotic Bcl-2 members (e.g. Mcl-1, Bcl-w or
A1) on Ca2 + homeostasis has yet to be investigated.3. ER CA2+ and Pro-apoptotic Bcl-2 proteins
Consistent with the concept that Bcl-2 family members
regulate similar aspects of cell physiology, recent investi-
gation has demonstrated that the pro-apoptotic proteins Bax
and Bak also modulate [Ca2 +]ER [35–37]. In human PC-3
prostate adenocarcinoma cells, ectopically expressed Bax or
Bak is located in both mitochondria and the ER. The
expression of these proteins causes a decrease in [Ca2 +]ER,
which can be inhibited by Bcl-2. In addition, the Bak/Bax-induced decrease in [Ca2 +]ER causes a corresponding in-
crease in uptake of Ca2 + into mitochondria. Furthermore,
inhibition of mitochondrial Ca2 + uptake by treatment with
RU360, an inhibitor of the Ca2 + uniporter, inhibits the
release of cytochrome c and apoptosis induced by Bak/
Bax overexpression [35]. It is interesting to note that in
these cells, expression of Bcl-2 inhibits the release of ER
Ca2 + induced by Bax expression. Whether this is the result
of direct interaction between Bcl-2 and Bax or of Bcl-2
regulating Ca2 + levels independently of Bax remains to be
determined.
In a human prostate cancer cell line (DU-145) that is
deficient in Bax expression, ER Ca2 + is not released to the
cytoplasm following staurosporine treatment. Ectopic ex-
pression of Bax in DU-145 cells restored the staurosporine-
induced increase in cytoplasmic Ca2 + and cytochrome c
release [36]. Prolonged overexpression of Bax in DU-145
cells caused a further decrease in [Ca2 +]ER with levels
similar to those seen after staurosporine treatment. Thus,
studies with human prostate cell lines demonstrate that
overexpression of Bax or Bak results in decreased [Ca2 +]ER
and indicate that Bax is required for staurosporine-induced
release of Ca2 + from the ER.
The influence of Bax and Bak on intracellular Ca2 + has
also been examined in double knock-outs of mouse embry-
onic fibroblasts (MEFs) where both the Bak and Bax alleles
were deleted [37]. As measured by Fura-2 and ER-targeted
aequorin, double knock-out cells have decreased [Ca2 +]ER.
As a consequence, these cells are more resistant to the lipid
second messengers ceramide and arachidonic acid, which
induce cell death by increasing cytoplasmic Ca2 +. Ectopic
expression of HA-tagged-Bax restores [Ca2 +]ER to levels
seen in wild-type MEFs and restores ceramide-induced cell
death. Thus, in contrast to experiments with prostate cancer
cells, the lack of Bax expression causes a decrease [Ca2 +]ER
in MEFs. Aside from the different cell types studied, the
apparently contradictory results may be due to differences in
the time course and level of Bax expression. When
expressed transiently at high levels, Bax causes the release
of [Ca2 +]ER; however, at low levels Bax appears to increase
[Ca2 +]ER.
In studies using the double knock-out MEFs, HA-tagged-
Bax was targeted to mitochondria by adding the mitochon-
drial targeting sequence for inner membrane protein cyto-
chrome c oxidase (subunit VIII) to the amino-terminus of
HA-Bax. Unlike expression of wild-type Bax, expression of
this mutant did not restore [Ca2 +]ER. Therefore, overexpres-
sion of SERCA was used to increase [Ca2 +]ER to levels
close to that of wild-type. By comparing double knock-out
MEFs expressing either SERCA, mitochondrial-targeted
Bax or both, the authors were able to separate the effects
of alterations in [Ca2 +]ER from those of Bax on mitochon-
dria. SERCA expression was required to restore cell death
mediated by lipid second messengers; while tBid-induced
apoptosis required the presence of Bax at the mitochondria.
In contrast, induction of cell death in the double knock-outs
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expression of both SERCA and the mutant Bax associated
with mitochondria. Thus, Bax appears to function at both
the ER and mitochondria in response to many death stimuli.
Although this is an elegant experimental system to
investigate organelle-specific functions for Bax, several
limitations are evident. Unlike Bcl-2 which is constitutively
integrated into membranes, Bax is normally located in the
cytoplasm or peripherally associated with membranes. Forc-
ing Bax to be constitutively bound to membranes removes
the translocation step that is important for regulation of Bax
activity [38–42]. The carboxy-terminal tail of Bax is
required for membrane association [5,39]; however, the
amino-terminus of Bax may play a role in membrane
localization and function [43–45]. Thus altering this region,
by adding an HA-tag and/or a mitochondrial targeting
sequence may further alter Bax function. It remains to be
determined if more subtle mutants of Bax (e.g. BaxS184V
[39,46]) that strongly enhance Bax-induced apoptosis also
have effects on [Ca2 +]ER. It would also be interesting to
determine what effect regulated expression of ER-specific
Bax mutants, reported to be too toxic to generate in the
double knock-outs [37], have on the regulation of [Ca2 +]ER.
Together, these studies suggest the following role for pro-
apoptotic Bcl-2 members in the regulation of [Ca2 +]ER: in
healthy cells the pro-apoptotic proteins Bak and/or Bax
maintain [Ca2 +]ER. However, during apoptosis elicited by
staurosporine or Bax overexpression, Bax and Bak cause the
release of Ca2 + from the ER. This switch in activity could
be due to a conformational change or an increased amount
of protein integrated into the ER membrane. If this is true,
then stable expression of Bak (which is constitutively
integrated into membranes) in the double knock-out cells
may not restore release of ER Ca2 + during apoptosis since
induction of apoptosis would be unlikely to increase the
amount of Bak at the membrane except perhaps by de novo
synthesis. The results obtained after selective Bax relocal-
ization suggest that Bak and Bax are not as functionally
interchangeable as is usually proposed. Furthermore, trans-
location of Bax to the ER may be regulated differently than
translocation to mitochondria.
Thus, the literature indicates that in different circum-
stances [Ca2 +]ER can be regulated in either direction by both
pro- and anti-apoptotic Bcl-2 proteins. Bcl-2 can decrease
[Ca2 +]ER [22,23] yet, depletion of [Ca
2 +]ER can have
detrimental effects on the cell [47]. Therefore, a delicate
balance must exist between the activities of pro- and anti-
apoptotic proteins in the regulation of [Ca2 +]ER. The pres-
ence of a Ca2 + gradient between the ER (high) and the
cytoplasm (low) indicates that regulation of [Ca2 +]ER by
Bcl-2 proteins is unlikely to be explained solely by the
ability of these proteins to function as ion selective pores:
how would Bax/Bak ‘pump’ Ca2 + into the ER against a pre-
existing concentration gradient? Since Bcl-2 interacts with
SERCA and Bcl-XL decreases IP3R expression, perhaps
Bax and/or Bak also directly interact with and modulateexisting Ca2 + channels/pumps to regulate [Ca2 +]ER inde-
pendently of Bcl-2/Bcl-XL. Alternatively, interactions be-
tween pro- and anti-apoptotic Bcl-2 family members via BH
domains may be required to regulate [Ca2 +]ER, or oligo-
merization and pore formation may be required. Clearly,
these intriguing results suggest that many possibilities
remain to be explored.4. Other functions for Bcl-2 members at the ER
4.1. Bap31
Aside from the SERCA pump, another protein that
interacts with Bcl-2 at the ER is the integral membrane
protein Bap31 [48]. Bap31 forms a complex with pro-
Caspase-8L and either Bcl-2 or Bcl-XL at the ER [49].
When apoptosis is induced by activation of the Fas death
receptor or by expression of adenoviral transforming
protein E1A, Bap31 is cleaved by either Caspase-8 or
Caspase-1 into a membrane integrated fragment (termed
p20) that can efficiently induce apoptosis when expressed
alone [48]. Expression of a mutant Bap31 resistant to
cleavage by caspases inhibited cytoplasmic membrane
blebbing, actin redistribution and cytochrome c release
following Fas stimulation [50]. Expression of Bcl-2 inhib-
its the cleavage of Bap31 [49], and the pro-apoptotic
activity of the p20 fragment [48]. Bap31 also interacts
with myosin heavy chain and g-actin. Fas stimulation
disrupts both of these interactions, and the p20 cleavage
fragment is unable to interact with g-actin [51]. Thus the
absence of specific morphological changes seen with the
expression of caspase resistant Bap31 may be attributed to
the prolonged tethering of Bap31 to actomyosin com-
plexes. Ectopic expression of the p20 fragment of Bap31
induces the release of ER Ca2 +, leading to increased Ca2 +
uptake by mitochondria and recruitment of dynamin-relat-
ed protein (Drp1) to mitochondria causing mitochondrial
fission [52].
Bap31 also interacts with the putative ion channel A4.
Expression of caspase-resistant Bap31 in combination with
A4 inhibits Fas-induced cell death [41]. Bap31 cleavage
was not required for Bax translocation to mitochondria, but
was required for Bax oligomerization. It is not clear how
Bap31 cleavage at ER contributes to Bax oligomerization at
mitochondria; however, it may be related to the Ca2 +
signaling initiated by the p20 Bap31 fragment.
Spike is a BH3-only protein that is localized primarily to
the ER [53]. Interactions between Spike and Bap31 displace
the Bap31:Bcl-XL interaction, suggesting that Spike regu-
lates Bap31 activity. In addition, a mutant version of Spike
that does not bind to Bap31 functioned as a dominant
negative, inhibiting Fas-induced apoptosis as effectively as
Bcl-XL expression. Taken together these experiments sug-
gest a compelling model for the regulation of apoptosis at
the ER via the Bap31 complex (Fig. 1).
Fig. 1. Bap31 complex and apoptosis. In healthy cells, Bap31 exists as an integral ER membrane protein, possibly tethered to the cytoskeleton through
interactions with g-actin. Upon stimulation with the death receptor protein Fas or E1A, Bap31 forms a complex with Bcl-XL and pro-Caspase-8L. In this state,
a cell is protected from cell death. If the BH3 protein, Spike, is activated and can overcome the anti-apoptotic Bcl-XL function, it then displaces the interaction
between Bap31 and Bcl-XL. This allows for the activation of pro-Caspase-8 to Caspase-8 (perhaps through multimerization of Bap31). Cleavage of Bap31
releases its tether on the cytoskeleton allowing its re-arrangement. In addition, the p20 membrane integrated fragment may also allow for the release of Ca2 +
from the ER.
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Aside from interactions with ER resident proteins and
membrane-bound pro-apoptotic family members that trans-
locate to the ER; Bcl-2 may function by sequestering other
pro-apoptotic factors. Consistent with this notion, Bad-
induced cell death can be inhibited by ER-localized Bcl-2
[46]. Co-expression of Bad- and the ER-restricted Bcl-2
mutant, Bcl2-cb5, sequestered Bad to the ER. Furthermore,
disruption of the Bad binding pocket on Bcl2-cb5 (BH1
mutant G145E) prevented the interaction of Bcl-2 with Bad
and rendered Bcl-2 ineffective at inhibiting Bad-induced
death [46]. The need for a direct interaction between Bcl2-
cb5 and Bad to inhibit apoptosis argues that ER-localized
Bcl-2 inhibits pro-apoptotic family members by sequester-
ing them away from other intracellular targets. Other non-
Bcl-2 cytosolic proteins that interact with Bcl-2 (e.g.
calcineurin, raf-1, etc., reviewed in Ref. [54]) may be
similarly regulated.
4.3. BIK
Pro-apoptotic Bcl-2 proteins may elicit cell death
through mechanisms other than Ca2 + regulation. Replacing
the tail-anchor of the pro-apoptotic BH3 protein BIK with
the corresponding sequence from the ER-specific isoform
of cytochrome b5 to generate an ER-targeted BIK (BIK-
cb5) protein. This BIK mutant causes the release ofmitochondrial cytochrome c independent of both Ca2 +
release from the ER and the mitochondrial permeability
transition pore [55]. These effects were also seen in vitro
using cytosol, mitochondria and ER microsomes generated
from Bax / cells indicating that Bax is not required
for BIK-cb5 to cause cytochrome c release. However,
cytochrome c release required both a cytosolic component
and the continued presence of ER microsomes, suggesting
that ER signaling molecules either activate or are activated
by cytoplasmic components to alter mitochondrial activity.
It is unknown to what extent Bak can substitute for Bax,
as these experiments were not performed in double knock-
out cells. Nevertheless, this system can be used to isolate
and identify cytosolic and ER components required to
trigger cytochrome c release, and may greatly increase
our understanding of the role of ER in the regulation of
cell death.5. Other potential Bcl-2 targets in the ER
5.1. Cellular pH changes
Somatostatin induces apoptosis in susceptible cells via
acidification of the cytoplasm. Acidification depends on the
activity of Src homology 2 tyrosine phosphatase 1 (SHP-1)
and can be inhibited by Bcl-2 [56]. However, if cells are
artificially acidified by the proton ionophore, nigericin, and
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Thus, Bcl-2 inhibits somatostatin-induced apoptosis up-
stream of acidification. Decreases in cellular pH can be
prevented by Caspase-8 inhibition and may be mediated
Na+/K+ proton exchangers at the ER, nuclear envelope and/
or endosomes [57]. Because, Bcl2-cb5 inhibits somatostat-
in-induced apoptosis upstream of acidification (Coimbatore
Srikant, personal communication) it is likely that inhibition
of acidification is regulated by one or more ER proteins,
perhaps by Bcl-2 directly modulating an ER-specific Na+/
K+ proton exchanger. It would be interesting to determine if
the Caspase-8 activity required for acidification is actually
the ER-specific isoform, Caspase-8L; if so, Bap31 may be
the relevant substrate. Alternately, Caspase-8L may cleave
another protein that regulates acidification.
5.2. Unfolded protein response
ER stress, induced by brefeldinA or tunicamycin, acti-
vates the unfolded protein response (UPR) (recently re-
viewed in Ref. [58]). The accumulation of unfolded
proteins in the lumen of the ER activates the transmembrane
Ser/Thr Kinase, Ire1-a [59], which then activates the c-Jun
NH2-terminal Kinase (JNK) pathway to induce apoptosis
[60]. In addition to JNK activation, UPR also activates
PKR-like ER kinase (PERK) causing it to phosphorylate
the translation initiation factor eIF2-a, and thereby decreas-
ing protein synthesis [61]. Expression of ER-restricted Bcl-2
can inhibit BrefeldinA- and tunicamycin-induced cell death
[30]; however, the stage in the process and the targets that
Bcl-2 regulates are not known.6. Bcl-2 members at locations other than the ER or
mitochondria
6.1. Cytoskeleton
Although this review has focused on Bcl-2 family
members function at the ER, Bcl-2 family members have
also been identified in other locations within the cell (Table
1). The BH3-only protein Bim has been shown to interact
with the dynein motor complex of the cytoskeleton. In
MCF-7 cells, induction of apoptosis with taxol releases
Bim from the cytoskeleton to permit its translocation to
heavy membranes and the nuclear membrane/ER [62]. Bmf
also interacts with the cytoskeleton [63]. Phosphorylation of
Bmf and Bim by JNK releases them from the cytoskeleton
[64] and stimulates apoptosis. In addition, the pro-apoptotic
protein Bad interacts with 14–3–3 scaffold proteins in its
inactive phosphorylated state [65]. Localization at the cyto-
skeleton appears to sequester pro-apoptotic Bcl-2 proteins
thereby preventing their activation and targeting the mito-
chondria and/or ER. As several different pro-apoptotic Bcl-2
proteins are located at different sites within the cytoskeleton,
and full-length Bap31 also binds to the cytoskeleton thissuggests that Bcl-2 family members may actively participate
in the rearrangement of the cytoskeleton during cell death.
6.2. Lysosomes
Inhibition of PI-3 kinase sensitizes vascular endothelial
cells to cytokine-initiated apoptosis that involves release of
cathepsins from lysosomes. In this form of programmed cell
death, Cathepsin B translocates from lysosomes to the
cytosol prior to the activation of caspases. While Bcl-2
has been shown to inhibit this form of cell death, the role of
subcellular localization was not examined [66]. Oxidative
stress has also been reported to induce apoptosis in part via
lysosomal leakage that can be inhibited by Bcl-2. Unlike
other Bcl-2 functions, it has been reported that phosphory-
lation of Bcl-2 is required for Bcl-2 to effectively inhibit
lysosomal rupture in response to oxidative damage [67]. In
most cells, phosphorylation of endogenous Bcl-2 is low
( < 10%). However, Bcl-2 mutants located in the cytoplasm
due to removal of the tail-anchor are efficiently phosphor-
ylated (f 50%). Therefore, it may be that the small fraction
of Bcl-2 that is phosphorylated and that prevents lysosomal
rupture is not localized at the ER or mitochondria.
Thus, a wealth of data indicate that apoptosis is regulated
at multiple sites within the cell. As additional roles for other
organelles and subcellular locations in apoptosis [68] are
more thoroughly investigated, other functions for the Bcl-2
family outside of the ER and mitochondria may yet be
identified.7. Mutants of Bcl-2 with restricted subcellular
localization
One powerful method to determine the relative contribu-
tion of Bcl-2 family proteins at the ER or mitochondria is
the use of mutants restricted to specific subcellular loca-
tions. This has been an important approach in our lab and in
many others over the last decade. Using this approach, we
generated a mutant Bcl-2 protein (Bcl2-cb5) restricted to the
ER in mammalian cells [13]. This mutant was made by
exchanging the carboxyl-terminal tail-anchor of wild-type
Bcl-2 with the corresponding sequence from an ER-specific
isoform of cytochrome b5. A similar approach was used to
restrict Bcl-2 to the mitochondria except that the tail-anchor
of Bcl-2 was exchanged for the membrane anchor of the
ActA from L. monocytogenes [13].
We and other investigators have demonstrated that Bcl2-
cb5 can inhibit cell death induced by a variety of apoptotic
stimuli including serum starvation [13], brefeldinA and
tunicamycin [30], DNA damage [69], Bad expression
[46], ceramide and staurosporine [31]. In Mcf-7 cells,
apoptosis induced by somatostatin analogues can only be
blocked by Bcl-2 at the ER and not by Bcl-2-targeted
exclusively to mitochondria (Coimbatore Srikant, personal
communication). In these cells, doxorubicin-induced cell
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ER (Fiebig A., Zhu W., Leber B. and Andrews D.W.,
unpublished observations). These observations suggest that
the relative importance of either the ER or mitochondria as
the critical site in the regulation of cell death varies with the
apoptotic stimuli.
In Rat-1mycER cells (in which myc activity is inducible
with estrogen), Bcl2-cb5 prevents apoptosis induced by
serum starvation, ceramide or staurosporine, but not etopo-
side or tertbutyl hydroperoxide [31]. Interestingly, apoptosis
induced by either ceramide or serum starvation is charac-
terized by early loss of mitochondrial membrane potential
that is followed by the release of cytochrome c, whereas
etoposide triggers translocation of Bax to mitochondria
where it undergoes a conformational change and causes
the release of cytochrome c. In this case, cytochrome c
release precedes loss of mitochondrial membrane potential
[31]. Thus, one difference between ER- and mitochondria-
regulated apoptosis is the order of mitochondrial dysfunc-
tion events, indicating the presence of multiple pathways
leading to cell death. As discussed previously, restoration of
wild-type kinetics of etoposide-induced apoptosis to Bax/
Bak double-knock-out cells required both ER Ca2 + and Bax
at mitochondria [37]. Taken together, these observations
suggest that either Bcl2-cb5 is not able to prevent ER Ca2 +
release by etoposide, or that inhibition of Ca2 + release is not
sufficient to inhibit etoposide-induced cell death. Consistent
with the latter, expression of Bcl-2 does not appear to inhibit
the release of Ca2 + from the ER in either doxorubicin- [70]
or thapsigargin- [47] induced cell death. In addition, ex-
pression of SERCA to increase ER Ca2 + had a marginal
effect on the kinetics of cell death following brefeldinA
treatment that could be inhibited by Bcl2-cb5 expression
[30]. In contrast, expression of mitochondrial-associated
Bax in this system enhanced the kinetics of apoptosis
considerably [37]. Thus, the use of organelle-targeted
mutants (Bcl-2 and Bax) together with other studies suggest
that Bcl-2 at the ER is regulating more than just Ca2 + and
that Ca2 + may not be the critical signal for some death
stimuli. As other locations within the cell are identified as
important in the regulation of apoptosis, the organelle-
specific contribution to cell death can be determined using
a similar approach, but with different targeting sequences.8. Summary
The Bcl-2 family of proteins regulates cell death at both
the ER and mitochondria. The recent observation of pro-
and anti-apoptotic Bcl-2 members at the ER in cells reaf-
firms the importance of the ER in the regulation of apopto-
sis. Bcl-2 family members modulate ER Ca2 + levels: in
general, pro-apoptotic members decrease ER Ca2 + during
cell death while anti-apoptotic Bcl-2 members have the
opposite effect. At the ER, Bcl-2 members not only regulate
Ca2 + homeostasis, but also interact with ER proteins such asBap31. As Bap31 and the pro-apoptotic family members
Bim and Bmf interact with the cytoskeleton, this suggests a
role for ER-associated Bcl-2 molecules in the rearrangement
of the cytoskeleton during apoptosis. Examining the indi-
vidual contributions of ER-associated Bcl-2 members sug-
gests that the ER can act upstream of mitochondria in the
initiation of apoptosis, and in some circumstances it can act
independently of mitochondria. The use of organelle-re-
stricted mutants has provided valuable insight into the
importance and contribution of the ER in the regulation of
apoptosis. These mutants will also be valuable in determin-
ing the critical sites in other apoptotic pathways where Bcl-2
family members function, and may thus aid in identifying
new therapeutic targets.References
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